Outlook on the Bruton's Tyrosine Kinase Inhibitors Global Industry to 2024 - Increasing Diabetic Population is Driving the Market - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Bruton's Tyrosine Kinase (BTK) Inhibitors Market: Size & Forecast with Impact Analysis of COVID-19 (2020-2024)" report has been added to ResearchAndMarkets.com's offering.

The report titled Global Bruton's Tyrosine Kinase (BTK) Inhibitors Market: Size & Forecast with Impact Analysis of COVID-19 (2020-2024), provides an in-depth analysis of the global bruton's tyrosine kinase (BTK) inhibitors market with description of market sizing and growth. The analysis includes market by value, by drug and by region. Furthermore, the report also provides detailed drug and regional analysis.

Moreover, the report also assesses the key opportunities in the market and outlines the factors that are and would be driving the growth of the industry. Growth of the overall global bruton's tyrosine kinase (BTK) inhibitors market has also been forecasted for the years 2020-2024, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

Company Coverage

• Johnson & Johnson
• AbbVie Inc.
• AstraZeneca
• BeiGene

Bruton's Tyrosine Kinase (BTK) is a major component of the B-cell receptor signalling pathway, which is an important regulator of cell proliferation and cell survival in numerous lymphomas (mainly NHL). Lymphomas are hematologic cancers involving lymphoceles of the immune system. They can be broadly categorized into non-Hodgkin's lymphomas (NHL), and Hodgkin Lymphoma (HL). NHL consists of a heterogeneous group of malignancies arising from lymphoid tissues.

Furthermore, BTK inhibitors block B-cell receptor (BCR) induced BTK activation and its downstream signalling. Successful blockage of BTK activation would result in growth inhibition and cell death of B-cells. B-cell lymphomas can be categorized into aggressive NHL, such as diffuse large B-Cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and burkitt's lymphoma (BL), and indolent NHL, such as chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), follicular lymphoma (FL), marginal zone lymphoma (MZL), CNSL and WM.

The global bruton's tyrosine kinase (BTK) inhibitors market has augmented progressively over the years and the market is further anticipated to incline during the forecasted years 2020 to 2024. The market would propel owing to numerous growth drivers like growth in the geriatric population, rising global healthcare expenditure, surging urban population, increasing diabetic population, escalating number of cancer patients and rising literacy rate.

However, the market faces some challenges which are hindering the growth of the market. Some of the foremost challenges faced by the industry are rising prevalence of cardiovascular disease, drug acceptance and legal obligations. Whereas, the market growth would be further supported by various market trends like IMBRUVICA plus Rituximab, BRUKINSA (zanubrutinib) and Brain-Penetrant BTK Inhibitor.

Market Dynamics

Growth Drivers

• Growth in Geriatric Population
• Rising Global Healthcare Expenditure
• Surging Urban Population
• Increasing Diabetic Population
• Escalating Number of Cancer Patients
• Rising Literacy Rate

Challenges

• Rising Prevalence of Cardiovascular Disease
• Drug Acceptance
• Legal Obligations

Market Trends

• IMBRUVICA plus Rituximab
• BRUKINSA (zanubrutinib)
• Brain-Penetrant BTK Inhibitor
  

For more information about this report visit https://www.researchandmarkets.com/r/ye72ww